Cargando…

Feasibility of genetic testing for cancer risk assessment programme in Nigeria

BACKGROUND: A high frequency of BRCA mutations has been established in Nigerian breast cancer (BC) patients. Recently, patients’ and first-degree relatives’ interest have been raised on cancer genetic risk assessment through our awareness activities in Nigeria. This led to the emergence of nurse-led...

Descripción completa

Detalles Bibliográficos
Autores principales: Adejumo, Prisca O, Aniagwu, Toyin I G, Awolude, Olutosin A, Oni, Abiodun O, Ajayi, Olubunmi O, Fagbenle, Omolara, Ogungbade, Dasola, Kochheiser, Makayla, Ogundiran, Temidayo, Olopade, Olufunmilayo I
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cancer Intelligence 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580592/
https://www.ncbi.nlm.nih.gov/pubmed/34824606
http://dx.doi.org/10.3332/ecancer.2021.1283
_version_ 1784596635332902912
author Adejumo, Prisca O
Aniagwu, Toyin I G
Awolude, Olutosin A
Oni, Abiodun O
Ajayi, Olubunmi O
Fagbenle, Omolara
Ogungbade, Dasola
Kochheiser, Makayla
Ogundiran, Temidayo
Olopade, Olufunmilayo I
author_facet Adejumo, Prisca O
Aniagwu, Toyin I G
Awolude, Olutosin A
Oni, Abiodun O
Ajayi, Olubunmi O
Fagbenle, Omolara
Ogungbade, Dasola
Kochheiser, Makayla
Ogundiran, Temidayo
Olopade, Olufunmilayo I
author_sort Adejumo, Prisca O
collection PubMed
description BACKGROUND: A high frequency of BRCA mutations has been established in Nigerian breast cancer (BC) patients. Recently, patients’ and first-degree relatives’ interest have been raised on cancer genetic risk assessment through our awareness activities in Nigeria. This led to the emergence of nurse-led cancer genetic counselling (CGC) and testing aimed at providing standard-of-care for individuals at increased risk of hereditary breast and ovarian cancers. METHODS: In June 2018, CGC and testing of patients with BC and ovarian cancer (OC) commenced in collaboration with Color Genomics Inc. for a 30-panel gene testing. Previously trained nurses in CGC at the University College Hospital, Ibadan offered genetic counselling (GC) to willing patients with BC and gynaecological cancer in four out-patient oncology clinics and departments for the pilot study. Consultation consisted of CGC, patient’s history, pedigree and sample collection for genetic testing (GT). RESULTS: Forty-seven patients – 40 with BC, five with OC and two with endometrial cancer received GC, and all chose to undergo GT. The average age at testing was 48.2 ± 12.1 years. Eight women reported a known family cancer history and there were more perceived benefits than barriers to GT with the patients experiencing the desire for none of their relative to have cancer. Results revealed no mutations in 27 (57.4%), 16 (4.0%) variants of unknown significance and 4 (8.5%) pathogenic mutations. CONCLUSION: Personalised cancer care utilises GC and testing for cancer risk assessment towards prevention and early detection in high risk women. The study indicates the necessity of expanded cancer genetic services for integration into patient care and cancer prevention.
format Online
Article
Text
id pubmed-8580592
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cancer Intelligence
record_format MEDLINE/PubMed
spelling pubmed-85805922021-11-24 Feasibility of genetic testing for cancer risk assessment programme in Nigeria Adejumo, Prisca O Aniagwu, Toyin I G Awolude, Olutosin A Oni, Abiodun O Ajayi, Olubunmi O Fagbenle, Omolara Ogungbade, Dasola Kochheiser, Makayla Ogundiran, Temidayo Olopade, Olufunmilayo I Ecancermedicalscience Research BACKGROUND: A high frequency of BRCA mutations has been established in Nigerian breast cancer (BC) patients. Recently, patients’ and first-degree relatives’ interest have been raised on cancer genetic risk assessment through our awareness activities in Nigeria. This led to the emergence of nurse-led cancer genetic counselling (CGC) and testing aimed at providing standard-of-care for individuals at increased risk of hereditary breast and ovarian cancers. METHODS: In June 2018, CGC and testing of patients with BC and ovarian cancer (OC) commenced in collaboration with Color Genomics Inc. for a 30-panel gene testing. Previously trained nurses in CGC at the University College Hospital, Ibadan offered genetic counselling (GC) to willing patients with BC and gynaecological cancer in four out-patient oncology clinics and departments for the pilot study. Consultation consisted of CGC, patient’s history, pedigree and sample collection for genetic testing (GT). RESULTS: Forty-seven patients – 40 with BC, five with OC and two with endometrial cancer received GC, and all chose to undergo GT. The average age at testing was 48.2 ± 12.1 years. Eight women reported a known family cancer history and there were more perceived benefits than barriers to GT with the patients experiencing the desire for none of their relative to have cancer. Results revealed no mutations in 27 (57.4%), 16 (4.0%) variants of unknown significance and 4 (8.5%) pathogenic mutations. CONCLUSION: Personalised cancer care utilises GC and testing for cancer risk assessment towards prevention and early detection in high risk women. The study indicates the necessity of expanded cancer genetic services for integration into patient care and cancer prevention. Cancer Intelligence 2021-09-07 /pmc/articles/PMC8580592/ /pubmed/34824606 http://dx.doi.org/10.3332/ecancer.2021.1283 Text en © the authors; licensee ecancermedicalscience. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0 (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Adejumo, Prisca O
Aniagwu, Toyin I G
Awolude, Olutosin A
Oni, Abiodun O
Ajayi, Olubunmi O
Fagbenle, Omolara
Ogungbade, Dasola
Kochheiser, Makayla
Ogundiran, Temidayo
Olopade, Olufunmilayo I
Feasibility of genetic testing for cancer risk assessment programme in Nigeria
title Feasibility of genetic testing for cancer risk assessment programme in Nigeria
title_full Feasibility of genetic testing for cancer risk assessment programme in Nigeria
title_fullStr Feasibility of genetic testing for cancer risk assessment programme in Nigeria
title_full_unstemmed Feasibility of genetic testing for cancer risk assessment programme in Nigeria
title_short Feasibility of genetic testing for cancer risk assessment programme in Nigeria
title_sort feasibility of genetic testing for cancer risk assessment programme in nigeria
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580592/
https://www.ncbi.nlm.nih.gov/pubmed/34824606
http://dx.doi.org/10.3332/ecancer.2021.1283
work_keys_str_mv AT adejumopriscao feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT aniagwutoyinig feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT awoludeolutosina feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT oniabioduno feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT ajayiolubunmio feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT fagbenleomolara feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT ogungbadedasola feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT kochheisermakayla feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT ogundirantemidayo feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria
AT olopadeolufunmilayoi feasibilityofgenetictestingforcancerriskassessmentprogrammeinnigeria